Equity Details
Price & Market Data
Price: $4.15
Daily Change: +$0.09 / 2.17%
Daily Range: $4.01 - $4.44
Market Cap: $9,402,558
Daily Volume: 76,999
Performance Metrics
1 Week: -13.00%
1 Month: -45.60%
3 Months: 66.10%
6 Months: -54.74%
1 Year: -84.81%
YTD: -9.37%
About Psyence Biomedical Ltd. (PBM)
The definitive guide to Psyence Biomedical Ltd. (PBM). Current price: 4.15, daily change: +$0.09 / 2.17%. Market cap: 9,402,558. All performance metrics you need.
Company Details
Employees: 12
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
